X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Aurobindo Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs AUROBINDO PHARMA - Comparison Results

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES AUROBINDO PHARMA ALKEM LABORATORIES/
AUROBINDO PHARMA
 
P/E (TTM) x - 14.3 - View Chart
P/BV x 7.4 3.7 200.2% View Chart
Dividend Yield % 0.6 0.4 138.7%  

Financials

 ALKEM LABORATORIES   AUROBINDO PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
AUROBINDO PHARMA
Mar-17
ALKEM LABORATORIES/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,589895 177.5%   
Low Rs1,232622 198.1%   
Sales per share (Unadj.) Rs417.5254.6 164.0%  
Earnings per share (Unadj.) Rs56.339.3 143.3%  
Cash flow per share (Unadj.) Rs64.746.6 138.9%  
Dividends per share (Unadj.) Rs12.702.50 508.0%  
Dividend yield (eoy) %0.90.3 273.2%  
Book value per share (Unadj.) Rs292.9160.0 183.1%  
Shares outstanding (eoy) m119.57585.88 20.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.43.0 113.4%   
Avg P/E ratio x25.119.3 129.7%  
P/CF ratio (eoy) x21.816.3 133.9%  
Price / Book Value ratio x4.84.7 101.5%  
Dividend payout %22.66.4 354.4%   
Avg Mkt Cap Rs m168,653444,390 38.0%   
No. of employees `000NA14.0 0.0%   
Total wages/salary Rs m9,17117,678 51.9%   
Avg. sales/employee Rs ThNM10,667.8-  
Avg. wages/employee Rs ThNM1,264.3-  
Avg. net profit/employee Rs ThNM1,645.8-  
INCOME DATA
Net Sales Rs m49,915149,157 33.5%  
Other income Rs m1,6451,159 142.0%   
Total revenues Rs m51,561150,316 34.3%   
Gross profit Rs m8,48234,343 24.7%  
Depreciation Rs m1,0064,276 23.5%   
Interest Rs m671667 100.5%   
Profit before tax Rs m8,45130,558 27.7%   
Minority Interest Rs m-11450 -226.7%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6067,597 21.1%   
Profit after tax Rs m6,73123,012 29.3%  
Gross profit margin %17.023.0 73.8%  
Effective tax rate %19.024.9 76.4%   
Net profit margin %13.515.4 87.4%  
BALANCE SHEET DATA
Current assets Rs m27,06292,062 29.4%   
Current liabilities Rs m15,32466,223 23.1%   
Net working cap to sales %23.517.3 135.7%  
Current ratio x1.81.4 127.0%  
Inventory Days Days67106 62.8%  
Debtors Days Days4168 61.0%  
Net fixed assets Rs m12,61062,919 20.0%   
Share capital Rs m239586 40.8%   
"Free" reserves Rs m34,49093,133 37.0%   
Net worth Rs m35,02793,719 37.4%   
Long term debt Rs m1,2121,814 66.8%   
Total assets Rs m54,387162,494 33.5%  
Interest coverage x13.646.8 29.1%   
Debt to equity ratio x00 178.7%  
Sales to assets ratio x0.90.9 100.0%   
Return on assets %13.614.6 93.4%  
Return on equity %19.224.6 78.3%  
Return on capital %24.932.7 75.9%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,56375,838 8.7%   
Fx outflow Rs m3,01230,224 10.0%   
Net fx Rs m3,55245,613 7.8%   
CASH FLOW
From Operations Rs m7,25932,786 22.1%  
From Investments Rs m1,864-17,870 -10.4%  
From Financial Activity Rs m-9,273-19,153 48.4%  
Net Cashflow Rs m-150-4,239 3.5%  

Share Holding

Indian Promoters % 66.9 54.1 123.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 8.0 416.4%  
FIIs % 0.0 27.7 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 10.2 -  
Shareholders   68,381 69,601 98.2%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   TORRENT PHARMA  NATCO PHARMA  AJANTA PHARMA  PFIZER  ALEMBIC PHARMA  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Feb 16, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS